Key result
Telemedicine-guided very low-dose INR self-control once weekly reduced the risk of grade III complications compared to low-dose INR.
Why the study?
Does telemedicine-guided very low-dose INR self-control reduce major bleeding and thrombotic events in patients with mechanical heart valve implants compared to low-dose INR self-control?
RCT (n=1,571)
Does telemedicine-guided very low-dose INR self-control reduce major bleeding and thrombotic events in patients with mechanical heart valve implants compared to low-dose INR self-control?
Telemedicine-guided very low-dose INR self-control reduces bleeding risk without increasing thrombotic risk in patients with mechanical aortic valve replacement, though twice-weekly testing was associated with increased mortality.
Answers are grounded in this paper and cite their sources.
Supports telemedicine-guided very low-dose INR self-control in mechanical valve patients; extends RCT evidence for fewer major complications.
AIM: To study in patients performing international normalized ratio (INR) self-control the efficacy and safety of an INR target range of 1.6-2.1 for aortic valve replacement (AVR) and 2.0-2.5 for mitral valve replacement (MVR) or double valve replacement (DVR). METHODS AND RESULTS: In total, 1304 patients undergoing AVR, 189 undergoing MVR and 78 undergoing DVR were randomly assigned to low-dose INR self-control (LOW group) (INR target range, AVR: 1.8-2.8; MVR/DVR: 2.5-3.5) or very low-dose INR self-control once a week (VLO group) and twice a week (VLT group) (INR target range, AVR: 1.6-2.1; MVR/DVR: 2.0-2.5), with electronically guided transfer of INR values. We compared grade III complications (major bleeding and thrombotic events; primary end-points) and overall mortality (secondary end-point) across the three treatment groups. FINDINGS: Two-year freedom from bleedings in the LOW, VLO, and VLT groups was 96.3, 98.6, and 99.1%, respectively (P = 0.008). The corresponding values for thrombotic events were 99.0, 99.8, and 98.9%, respectively (P = 0.258). The risk-adjusted composite of grade III complications was in the per-protocol population (reference: LOW-dose group) as follows: hazard ratio = 0.307 (95% CI: 0.102-0.926; P = 0.036) for the VLO group and = 0.241 (95% CI: 0.070-0.836; P = 0.025) for the VLT group. The corresponding values of 2-year mortality were = 1.685 (95% CI: 0.473-5.996; P = 0.421) for the VLO group and = 4.70 (95% CI: 1.62-13.60; P = 0.004) for the VLT group. CONCLUSION: Telemedicine-guided very low-dose INR self-control is comparable with low-dose INR in thrombotic risk, and is superior in bleeding risk. Weekly testing is sufficient. Given the small number of MVR and DVR patients, results are only valid for AVR patients.
No takes yet. Share an insight, caveat, or question.
Koertke et al. (2014) conducted an RCT in Mechanical heart valve implants (n=1,571). Very low-dose INR self-control vs. Low-dose INR self-control was evaluated on Composite of grade III complications (major bleeding and thrombotic events) (HR 0.307, 95% CI 0.102-0.926, p=0.036). Telemedicine-guided very low-dose INR self-control once weekly reduced the risk of grade III complications compared to low-dose INR.
Synapse has enriched 10 related papers. Consider them for comparative context: